AlphAIalphai — Financial news for AI agents
MeykaMAR 173 min read$AIRS

AirSculpt (AIRS) NASDAQ +51% after 12b-25 filing 16 Mar 2026: earnings Mar 20

AirSculpt Technologies, Inc. (AIRS) saw its stock jump over 51% on March 16, 2026, following a 12b-25 filing and preliminary 2025 revenue of $151.80 million. Investors are now focused on the upcoming earnings report on March 20, 2026, which will provide more clarity on finances and liquidity. Meyka AI projects a yearly target of $3.74 for AIRS, suggesting a 33.09% upside, while highlighting risks such as debt and negative EPS.

Original reporting
Meyka · Danny Kontos
Published Mar 17, 2026, 12:08 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 17, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$AIRS
Neutral
medium confidence
Mentioned
$AIRS
alphai data visualization · based on Meyka
Decision brief

The 30-second read

$AIRSNeutralMed
01

Why it matters

The stock's 51% jump suggests strong investor interest, possibly driven by optimism about future growth or strategic developments.

02

Market read

The event is significant within the medical aesthetics sector, influencing investor sentiment and stock performance.

03

What to watch

High debt levels and negative EPS projections pose significant risks that may outweigh short-term gains.

Timing: Immediate, as earnings report is scheduled for March 20, 2026.

Background

AirSculpt Technologies recently filed a 12b-25, indicating a need for additional capital, and reported preliminary revenue of $151.80 million for 2025.

Company-level read

Ticker impact

$AIRSNeutralMedium confidence
Context

High relevance due to recent stock surge and upcoming earnings report.

Expected impact

Potential short-term volatility with upward bias if earnings meet or exceed expectations; risk of decline if results disappoint.

Evidence & confidence

Recent stock jump indicates market anticipation; however, limited financial details and high debt levels introduce uncertainty.

Market effects

Sector

Potential positive sentiment in the medical aesthetics and cosmetic surgery sector due to AIRS's stock surge.

Regional

Limited regional impact; primarily affecting US-based markets.

Global

Minimal global relevance; sector-specific event.

Counterpoint

What could challenge this read

The stock surge may be overextended; earnings could reveal financial weaknesses, leading to a correction.

Key entities

  • Company
    AirSculpt Technologies

    A provider of medical aesthetic procedures specializing in body contouring.

Read at source← All news

Related articles

AUG 17
$AIRSMedAI 8/10

AirSculpt (AIRS) Q2 2026 Earnings Call Transcript

AirSculpt Technologies (AIRS) reported Q2 2026 revenue of $42.9M, down 3% from $44.0M a year earlier. Q2 case volume was 3,376, slightly down, while gross margin rose to 61.2%. Adjusted EBITDA was $4.9M. Full-year revenue guidance is $151M to $157M and Adjusted EBITDA $12M to $14M, revised lower on added marketing. Cash was $18.8M; debt was $44.2M.

fool.com6 min
AUG 10
$TENXHighAI 8/10

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

U.S. stock index futures edged higher as investors weighed fading Middle East deal hopes and upcoming inflation data. Tenax Therapeutics shares fell 84.2% after Phase 3 TNX-103 missed endpoints. Sionna Therapeutics dropped 92.1% after Phase 2a SION-719 failed. MarineMax rose over 34% on a reported $1.5B Safe Harbor Marinas buyout. AAON, Silence, Dole, and AirSculpt also moved premarket on updates.

investing.com7 min
AUG 10
$AIRSHighAI 9/10

Why is AirSculpt Technologies stock tumbling today?

Investing.com reports AirSculpt Technologies (AIRS) shares fell about 18.4% in pre-open after its Q2 fiscal 2026 earnings. Revenue was $42.9M, down 3% YoY, with net loss of $1.1M and Adjusted EBITDA $4.9M (11.5% margin). Guidance was revised to the lower end of $151–$157M revenue and Adjusted EBITDA $12–$14M.

investing.com4 min
AUG 10
$AIRSMed

Airsculpt Technologies, Inc. (AIRS): Results of Operations and Financial Condition

Airsculpt Technologies, Inc. (AIRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results Same Center Cases Up 1% for the Second Consecutive Quarter MIAMI BEACH, Fla., August 10, 2026 (GLOBE NEWSWIRE) – AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national pro

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min